Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On July18, 2017, we filed a preliminary prospectus supplement with the Securities and Exchange Commission, or the SEC, in which we disclosed that as of June 30, 2017, we had approximately $92.0 million of cash and cash equivalents and short-term investments. This amount is unaudited and preliminary, is subject to completion of financial closing procedures that could result in changes to the amount, and does not present all information necessary for an understanding of our financial condition as of June 30, 2017.
“At-The-Market” Facility Sales
to our At-The-Market Equity Offering Sales Agreement, dated June17, 2016, with Stifel, Nicolaus& Company, Incorporated, we sold an aggregate of 2,937,406 shares of common stock since March31, 2017 at an average public offering price of $8.24 per share, resulting in net proceeds of approximately $24.2 million.
About Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
Inovio Pharmaceuticals, Inc. (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza, Ebola, Middle East respiratory syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, the Company has a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses.
